Altimmune (ALT) Net Margin (2010 - 2025)

Altimmune (ALT) has 16 years of Net Margin data on file, last reported at 222653.85% in Q4 2025.

• Net Margin for Q4 2025 came in at 222653.85%, up 68625385.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 6939.02% (up 46835598.0% YoY), and the FY2025 annual result was 6939.02%, up 46835598.0% from the prior year.
• Net Margin grew to 222653.85% in Q4 2025 per ALT's latest filing, from 380280.0% in the prior quarter.
• Over five years, Net Margin peaked at 222653.85% in Q4 2025 and troughed at 1175800.0% in Q3 2022.
• A 5-year average of 231074.74% and a median of 173665.48% in 2023 frame the typical range for Net Margin.
• The sharpest annual moves came in 2022 and 2023: Net Margin slumped 115459114 bps in 2022, then soared 117008978 bps in 2023.
• A 5-year view of Net Margin shows it stood at 164.24% in 2021, then jumped by 119745 bps to 196500.0% in 2022, then sank by 112 bps to 24029.73% in 2023, then sank by 1829 bps to 463600.0% in 2024, then surged by 148 bps to 222653.85% in 2025.
• Business Quant data shows ALT's Net Margin at 222653.85% in Q4 2025, 380280.0% in Q3 2025, and 442920.0% in Q2 2025.